Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, multicenter Phase Ib clinical trial evaluating
TQB2858 injection in the treatment of advanced high-grade sarcoma. To evaluate the
preliminary efficacy and safety of TQB2858 injection in patients with advanced high-grade
sarcoma, and to explore the relevant biomarkers of TQB2858 injection.
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.